{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "P",
                    "position": "30"
                },
                "variant_string_id": "SNCA A30P"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta of the brain and is associated with the presence of intracellular inclusion bodies termed Lewy bodies (LBs). A significant fraction of the α - Synuclein (αSyn) in these structures is proteolytically processed. αSyn has been implicated in PD by molecular genetic data, including the A30P mutation.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes the disease mechanism of PD, including the role of αSyn and its proteolytic processing, and the involvement of the A30P mutation in PD.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used in - vitro assays including degradation assays, fibrillization assays, and oligomerization assays to evaluate the effect of the A30P mutation on αSyn in the presence of 20S proteasome and liposomes.",
                    "judgment": "Yes",
                    "reasoning": "The in - vitro assays used effectively model the processes of αSyn degradation, fibrillization, and oligomerization which are relevant to the disease mechanism of PD as described in Step 1.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The αSyn fibrillization assays were performed in triplicate. The oligomerization assays data were from three independent experiments. The study also used control experiments with fluorogenic peptides to show that the activity of 20S is not affected by liposomes. Wild - type αSyn was used as a control in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Both basic controls (wild - type αSyn) and replicates (fibrillization assays in triplicate and oligomerization assays from three independent experiments) were used in the assays.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3c: Variant Controls",
                    "extracted_paper_info": "The study compared the behavior of A30P - syn with wild - type αSyn and other disease - associated mutants (E46K - syn and A53T - syn) in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Known disease - associated mutants (E46K - syn and A53T - syn) were used as controls in the assays.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4a: Statistical Analyses",
                    "extracted_paper_info": "The data from the oligomerization assays were quantitated by densitometry and normalized, and mean and standard deviation were determined. However, no mention of OddsPath calculation.",
                    "judgment": "No",
                    "reasoning": "The paper does not calculate OddsPath for the functional data of the A30P variant.",
                    "next_step_or_outcome": "Proceed to Sub - step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4b: No OddsPath Calculation",
                    "extracted_paper_info": "The study used wild - type and two other disease - associated mutants (E46K - syn and A53T - syn) as controls in the oligomerization assays related to A30P - syn.",
                    "judgment": "Yes",
                    "reasoning": "The number of benign/pathogenic variant controls used is 3 (wild - type, E46K - syn, A53T - syn), which is less than 10.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The A30P variant in SNCA was studied using in - vitro assays relevant to PD pathogenesis. The assays had proper controls and replicates. Variant controls were also used. However, without OddsPath calculation and with less than 10 total benign/pathogenic variant controls, the functional evidence strength is PS3_supporting."
        },
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "E",
                    "alt": "K",
                    "position": "46"
                },
                "variant_string_id": "SNCA E46K"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta of the brain and is associated with the presence of intracellular inclusion bodies termed Lewy bodies (LBs). A significant fraction of the α - Synuclein (αSyn) in these structures is proteolytically processed. αSyn has been implicated in PD by molecular genetic data, including the E46K mutation.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes the disease mechanism of PD, including the role of αSyn and its proteolytic processing, and the involvement of the E46K mutation in PD.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used in - vitro assays including degradation assays, fibrillization assays, and oligomerization assays to evaluate the effect of the E46K mutation on αSyn in the presence of 20S proteasome and liposomes.",
                    "judgment": "Yes",
                    "reasoning": "The in - vitro assays used effectively model the processes of αSyn degradation, fibrillization, and oligomerization which are relevant to the disease mechanism of PD as described in Step 1.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The αSyn fibrillization assays were performed in triplicate. The oligomerization assays data were from three independent experiments. The study also used control experiments with fluorogenic peptides to show that the activity of 20S is not affected by liposomes. Wild - type αSyn was used as a control in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Both basic controls (wild - type αSyn) and replicates (fibrillization assays in triplicate and oligomerization assays from three independent experiments) were used in the assays.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3c: Variant Controls",
                    "extracted_paper_info": "The study compared the behavior of E46K - syn with wild - type αSyn and other disease - associated mutants (A30P - syn and A53T - syn) in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Known disease - associated mutants (A30P - syn and A53T - syn) were used as controls in the assays.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4a: Statistical Analyses",
                    "extracted_paper_info": "The data from the oligomerization assays were quantitated by densitometry and normalized, and mean and standard deviation were determined. However, no mention of OddsPath calculation.",
                    "judgment": "No",
                    "reasoning": "The paper does not calculate OddsPath for the functional data of the E46K variant.",
                    "next_step_or_outcome": "Proceed to Sub - step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4b: No OddsPath Calculation",
                    "extracted_paper_info": "The study used wild - type and two other disease - associated mutants (A30P - syn and A53T - syn) as controls in the oligomerization assays related to E46K - syn.",
                    "judgment": "Yes",
                    "reasoning": "The number of benign/pathogenic variant controls used is 3 (wild - type, A30P - syn, A53T - syn), which is less than 10.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The E46K variant in SNCA was studied using in - vitro assays relevant to PD pathogenesis. The assays had proper controls and replicates. Variant controls were also used. However, without OddsPath calculation and with less than 10 total benign/pathogenic variant controls, the functional evidence strength is PS3_supporting."
        },
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "T",
                    "position": "53"
                },
                "variant_string_id": "SNCA A53T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta of the brain and is associated with the presence of intracellular inclusion bodies termed Lewy bodies (LBs). A significant fraction of the α - Synuclein (αSyn) in these structures is proteolytically processed. αSyn has been implicated in PD by molecular genetic data, including the A53T mutation.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes the disease mechanism of PD, including the role of αSyn and its proteolytic processing, and the involvement of the A53T mutation in PD.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used in - vitro assays including degradation assays, fibrillization assays, and oligomerization assays to evaluate the effect of the A53T mutation on αSyn in the presence of 20S proteasome and liposomes.",
                    "judgment": "Yes",
                    "reasoning": "The in - vitro assays used effectively model the processes of αSyn degradation, fibrillization, and oligomerization which are relevant to the disease mechanism of PD as described in Step 1.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The αSyn fibrillization assays were performed in triplicate. The oligomerization assays data were from three independent experiments. The study also used control experiments with fluorogenic peptides to show that the activity of 20S is not affected by liposomes. Wild - type αSyn was used as a control in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Both basic controls (wild - type αSyn) and replicates (fibrillization assays in triplicate and oligomerization assays from three independent experiments) were used in the assays.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3c: Variant Controls",
                    "extracted_paper_info": "The study compared the behavior of A53T - syn with wild - type αSyn and other disease - associated mutants (A30P - syn and E46K - syn) in the assays.",
                    "judgment": "Yes",
                    "reasoning": "Known disease - associated mutants (A30P - syn and E46K - syn) were used as controls in the assays.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4a: Statistical Analyses",
                    "extracted_paper_info": "The data from the oligomerization assays were quantitated by densitometry and normalized, and mean and standard deviation were determined. However, no mention of OddsPath calculation.",
                    "judgment": "No",
                    "reasoning": "The paper does not calculate OddsPath for the functional data of the A53T variant.",
                    "next_step_or_outcome": "Proceed to Sub - step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4b: No OddsPath Calculation",
                    "extracted_paper_info": "The study used wild - type and two other disease - associated mutants (A30P - syn and E46K - syn) as controls in the oligomerization assays related to A53T - syn.",
                    "judgment": "Yes",
                    "reasoning": "The number of benign/pathogenic variant controls used is 3 (wild - type, A30P - syn, E46K - syn), which is less than 10.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The A53T variant in SNCA was studied using in - vitro assays relevant to PD pathogenesis. The assays had proper controls and replicates. Variant controls were also used. However, without OddsPath calculation and with less than 10 total benign/pathogenic variant controls, the functional evidence strength is PS3_supporting."
        }
    ]
}